SEC Form 4 · accession 0001209191-18-041549
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Ambrogi
Officer — Chief Operating Officer
Period of report
Jul 2, 2018
Accepted (ET)
Jul 5, 2018 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jul 2, 2018 | M | 27,825 | $7.03 | A | 174,383 | D | |
| Ordinary SharesF1 | Jul 2, 2018 | M | 29,565 | $7.48 | A | 203,948 | D | |
| Ordinary SharesF2 | Jul 2, 2018 | S | 57,390 | $31.48 | D | 146,558 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF3 | $7.03 | Jul 2, 2018 | M | 27,825 | A | — | Feb 20, 2023 | Ordinary Shares | 27,825 | 0 | D |
| Options to Buy Ordinary SharesF3 | $7.48 | Jul 2, 2018 | M | 29,565 | A | — | Feb 26, 2024 | Ordinary Shares | 29,565 | 0 | D |
Explanation of responses
- F1These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi.
- F2On July 2, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 57,390 shares in multiple trades at prices ranging from $31.00 to $31.95. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F3Fully vested as of the date hereof.